Figure 6.

The combination treatment of ABT263 and selinexor reduces tumor growth stronger than vehicle or single treatments in a patient-derived xenograft model of human GBM. (A) Patient-derived xenograft model (GBM12) was implanted subcutaneously in nude mice. Once tumors became palpable and were about to enter an exponential growth rate, four treatment groups were randomly assigned: A, Vehicle (Ctrl), ABT263, selinexor or ABT263 + selinexor (A + S). Two treatments were given, consisting of vehicle, 75 mg/kg ABT263, 10 mg/kg selinexor or the combination. Tumor growth was measured and is plotted as volume over time (days). Shown are means and SD. (B) for the same experiments described in A weight measurements were taken for the individual groups. (C) On the day of conclusion of the experiment described in A, statistical analysis was performed. Shown are means and SD. (D) Representative gross images of the individual groups are shown after conclusion of the experiment. A + S: ABT263 + selinexor. (E) Tumors from the individual groups were fixed, embedded in paraffin and paraffin section were stained with standard hematoxylin and eosin staining (H&E). Shown are representative images from the individual treatment groups. F, Tumors from the indicated groups were stained with TUNEL. Representative images are shown and arrows highlight TUNEL positive cells. *p < 0.05; **/***/****p < 0.01.